TRIZEDON MR 35 mg is a modified-release tablet containing Trimetazidine Dihydrochloride, a metabolic anti-ischemic agent. It works by inhibiting the enzyme 3-ketoacyl-CoA thiolase, which shifts myocardial energy production from fatty acid oxidation to glucose oxidation. This shift enhances energy production under ischemic conditions, improving heart function and reducing angina symptoms.